In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients. Some background Patients with NHL are often treated with targeted therapies....
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients. Some background Patients...
Read More
In a nutshell This study evaluated whether certain genetic markers affect how long patients respond to treatment for recurrent multiple myeloma (MM). This study found that patients without these genetic markers had better outcomes compared to patients who did have them. Some background Multiple myeloma is a type of cancer of the bone marrow that can...
Read More
In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...
Read More
In a nutshell This study evaluated the effectiveness of BEAM chemotherapy versus BUCYVP16 chemotherapy in patients with non-Hodgkin’s lymphoma (NHL) before autologous stem cell transplantation (ASCT). This study concluded that these regimens were similarly safe and effective for these patients before ASCT. Some background For patients with NHL...
Read MoreIn a nutshell This study aimed to investigate the long-term safety and effectiveness of inotuzumab ozogamicin (Besponsa) for patients with relapsed or unresponsive acute lymphoblastic leukemia. This study concluded that this treatment was safe and effective for these patients. Some background Inotuzumab ozogamicin (InO) is a targeted...
Read MoreIn a nutshell This phase 2 trial is evaluating the effectiveness of huCART19 cell therapy in young patients with high-risk B-cell acute lymphoblastic leukemia (ALL). The main outcome to be measured will be survival without a treatment-related complication. This study is being conducted in Philadelphia, Pennsylvania, United States. The details Acute...
Read More
In a nutshell This study investigated the effectiveness of pertuzumab (Perjeta) and trastuzumab (Herceptin) in patients with colorectal cancer and HER2 mutation (an abnormal gene). Researchers suggested that this treatment could be a safe option for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Some background...
Read More
In a nutshell This study investigated the effectiveness of the combined treatment FOLFIRI with aflibercept (Zaltrap) outside of clinical trials in patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that this treatment might be a safe second line option in patients who progressed after first-line...
Read More
In a nutshell This study aimed to compare outcomes for patients with Hodgkin’s lymphoma who received brentuximab vedotin (Adcetris) compared to chemotherapy before a stem cell transplant. This study concluded that patients who received brentuximab vedotin had a better survival. Some background Allogeneic hematopoietic stem cell...
Read More
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with leukemia/lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect...
Read More
In a nutshell This phase 2 trial will investigate the safety and effectiveness of tisotumab vedotin (TTV) for the treatment of solid tumors. The main outcome will be the response rate to treatment. This trial will take place in the United States, France, and Italy. The details Non-small cell lung cancer (NSCLC) is caused by excessive cell growth in...
Read More
